EG427, a gene therapy specialist focused on chronic neuro-urology indications, closed a €33 million (US$37.7 million) Series C after changing its brand identity, according to the report. The funding is expected to advance the lead program further in clinical development. The update emphasizes continued investor appetite for gene therapy programs that are moving through clinical milestones beyond early proof-of-concept. The company’s focus on chronic neuro-urology suggests an intention to address durable outcomes in longer-term conditions. Series C activity also signals that gene therapy development risk is being underwritten at later stages where clinical endpoints and operational execution are more visible to investors.